Viracta Therapeutics, Inc.

0.71 USD
+0.00 (+0.35%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Viracta Therapeutics, Inc. stock is down -13.41% since 30 days ago. The next earnings date is Aug 12, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 31.58% of the previous 18 May’s closed higher than April. 100% of analysts rate it a buy.

About Viracta Therapeutics, Inc.

Viracta Therapeutics, Inc. engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir. The company's development pipeline includesvecabrutinib, a clinical-stage non-covalent ITK/BTK inhibitor and VRx-510.